According to our previous studies, the expression levels of HER2 and ER in HR+/HER2+ breast cancer impact patient prognosis, and DFS is significantly shortened in patients with higher HER2 expression (p = 0.046; 5‐year DFS rate: 67% vs. 91%).7 The gene discussed is ESR1; the disease is breast carcinoma.